Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Athenex, Inc. (ATNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.1935+0.0075 (+4.03%)
At close: 04:00PM EST
0.1950 +0.00 (+0.78%)
After hours: 07:53PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1860
Open0.1900
Bid0.1900 x 1100
Ask0.1935 x 1200
Day's Range0.1862 - 0.1955
52 Week Range0.1180 - 1.2000
Volume1,380,276
Avg. Volume4,092,335
Market Cap21.153M
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Athenex Announces MHRA Decision on Oral Paclitaxel

    MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issuesAthenex plans to request a review of the MHRA decision by an independent panel The MHRA application was supplemented with safety data from the iSPY 2 study and no major clinical efficacy or safety concerns were expressed BUFFALO, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, a

  • GlobeNewswire

    Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

    Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroupBUFFALO, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions announced that collaborators at the Quantum Leap Healthcare Collaborative reported today that the Company’s oral paclitaxel plus encequ

  • GlobeNewswire

    Athenex Exits 503B Sterile Compounding Business

    Full-year 2022 product sales guidance maintained at 20-25% growth year-over-yearBUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the exit of its 503B sterile compounding business. 503B product sales accounted for approximately 19% of Athenex’s total product sales in the third quarter

Advertisement
Advertisement